trending Market Intelligence /marketintelligence/en/news-insights/trending/WqlZINOFSA2jSwW7eN4izg2 content esgSubNav
In This List

Another proxy firm backs CytRx reverse stock split plan

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond

Blog

University Essentials: From Crisis to Resilience – Navigating Sustainable Recovery

Blog

EV impact; vaccines to boost job market; coal supply constraints

Blog

Shore Capital is Now Available in S&P Global’s Aftermarket Research Collection


Another proxy firm backs CytRx reverse stock split plan

Institutional Shareholder Services Inc. recommended that CytRx Corp. shareholders vote in favor of the company's proposed reverse stock split at the upcoming Oct. 17 meeting.

The proxy advisory firm was echoing the same advice from Glass Lewis & Co.

The biopharmaceutical company is seeking shareholder approval to implement a 1-for-6 reverse stock split of both its authorized common and preferred stock in an attempt to regain compliance with Nasdaq's $1 minimum bid price requirement to maintain listing on the exchange.